Page last updated: 2024-11-07

beta-peltatin a methyl ether

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

beta-peltatin A methyl ether: isolated from Mexican plant Bursera fagaroides; antitumor agent of podophyllotoxin (III) class; RN given refers to (5alpha,5beta,8aalpha)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID159962
CHEMBL ID483004
CHEBI ID10437
SCHEMBL ID17041869
MeSH IDM0056029

Synonyms (18)

Synonym
furo[3',7]naphtho[2,3-d]-1,3-dioxol-6(5ah)-one, 5,8,8a,9-tetrahydro-10-methoxy-5-(3,4,5-trimethoxyphenyl)-, (5r-(5.alpha.,-5a.alpha.,8a.alpha.))-
nsc-126726
.beta.-peltatin, o-methyl-
peltatin, alpha methyl ether
nsc126726
38943-35-0
nsc35480
nsc-35480
23978-65-6
beta-peltatin a methyl ether
beta-peltatin-a methyl ether
chebi:10437 ,
CHEMBL483004
furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5ah)-one, 5,8,8a,9-tetrahydro-10-methoxy-5-(3,4,5-trimethoxyphenyl)-, (5r-(5alpha,5abeta,8aalpha))-
DTXSID70178700
SCHEMBL17041869
beta-peltatin-methyl-ether
Q27108637
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
lactoneAny cyclic carboxylic ester containing a 1-oxacycloalkan-2-one structure, or an analogue having unsaturation or heteroatoms replacing one or more carbon atoms of the ring.
lignanAny phenylpropanoid derived from phenylalanine via dimerization of substituted cinnamic alcohols, known as monolignols, to a dibenzylbutane skeleton. Note that while individual members of the class have names ending ...lignane, ...lignene, ...lignadiene, etc., the class names lignan, neolignan, etc., do not end with an "e".
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
6-methoxypodophyllotoxin biosynthesis014

Bioassays (4)

Assay IDTitleYearJournalArticle
AID398809Cytotoxicity against human KB cells
AID403994Antiviral activity against VSV infected in BHK cells assessed as inhibition of plaque formation1998Journal of natural products, Nov, Volume: 61, Issue:11
Antiviral activity of lignans.
AID1322968Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay2016Journal of natural products, 06-24, Volume: 79, Issue:6
Lignans from the Australian Endemic Plant Austrobaileya scandens.
AID403993Antiviral activity against HSV1 infected in monkey CV-1 cells assessed as inhibition of plaque formation1998Journal of natural products, Nov, Volume: 61, Issue:11
Antiviral activity of lignans.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (25.00)18.7374
1990's1 (25.00)18.2507
2000's0 (0.00)29.6817
2010's2 (50.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.38 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (16.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]